Pharma channel feed – Endpoints News

Pharma channel feed

Mylan wins tentative US approval for generic version of Lilly's Alimta — it could be years before it can be sold

6 years ago

Novartis preps a 2020 launch in multiple sclerosis as 2 successful pivotal trials set stage for an assault on Roche’s new star franchise

6 years ago

EMA follows FDA to approve Roche's Tecentriq combo for frontline use in triple negative breast cancer

6 years ago

Amgen’s legendary lawyer corps loses a major court fight attempting to quash PCSK9 rival from Sanofi, Regeneron

6 years ago

Tears for FAERS: Another FAERS disaster rumor slams Vertex shares in a Wall Street melee — but this time the tempest passed quickly

6 years ago

Bristol-Myers, AbbVie's multiple myeloma drug wins second EU nod as part of triple regimen

6 years ago

Purdue Pharma proposes $12B settlement to clean up opioid mess — report

6 years ago

Decades in the making, Kyowa Hakko Kirin finally wins FDA approval for add-on Parkinson's therapy

6 years ago

Top FDA exec Edward Cox jumps ship and joins Regeneron as new regulatory VP

6 years ago

For sale: Boston Children’s team touts a new CRISPR delivery system for triple-negative breast cancer — plus — after testing it in mice and cells

6 years ago

Oklahoma judge finds J&J guilty for its role in the opioid epidemic — but shares spike on $572M fine

6 years ago

Lilly's Taltz wins third approval, this time in patients with active ankylosing spondylitis

6 years ago

Top 20 by revenue: New analysis highlights huge impact of tax reform on many — but not all — of the top pharma giants

6 years ago

Olumiant from Lilly, Incyte clears third eczema study, but who will use it?

6 years ago

FDA asks why Novartis took two months to launch formal internal probe, after AveXis flagged data manipulation

6 years ago

Get as much Spravato as you can, Trump orders VA while suggesting J&J should offer it to veterans for free

6 years ago

An emboldened AstraZeneca splurges $95M on a priority review voucher. Where do they need the FDA to hustle up?

6 years ago

Sir Andrew Dillon, NICE's first — and only — chief executive to step down next year

6 years ago

AstraZeneca’s Imfinzi/treme combo strikes out — again — in lung cancer. Is it time for last rites?

6 years ago

Elanco to buy Bayer's animal health business for $7.6B, as dealmaking gathers steam in the sector

6 years ago

AstraZeneca's diabetes drug Farxiga helps patients with heart disease and without diabetes in landmark trial

6 years ago

Novartis spinoff Nabriva finally scores its first antibiotic approval

6 years ago

I’m not perfect: Novartis chief Vas Narasimhan almost apologizes in the wake of a new crisis

6 years ago

Celgene and the scientist who championed fedratinib's rise from Sanofi's R&D graveyard win FDA OK

6 years ago

First page Previous page 267 268 269270271 272 273 Next page Last page